GlassScriptPhysician profile
Michael Mastrangelo
NPI 1306802350
$15,305.62
in general payments reported to CMS, 2019-2025
12 companies · $1,273 in 2025
The $1,273 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,088 · 2021: $310 · 2022: $7,422 · 2023: $2,077 · 2024: $3,135 · 2025: $1,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,942 · Travel and Lodging: $2,543 · Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,941.87 |
| Travel and Lodging | $2,542.82 |
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,197.39 | 2019-2024 | |
| Tela Bio, INC. | $3,110.14 | 2023-2024 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Davol INC. | $2,457.45 | 2019-2025 | Phasix Mesh |
| Boston Scientific Corporation | $937.00 | 2019-2023 | Exalt Model D, Spyglass |
| Becton, Dickinson and Company | $161.23 | 2025 | Phasix Mesh |
| Medtronic, INC. | $142.77 | 2023 | Absorbatack |
| Conmed Corporation | $106.16 | 2023 | Airseal, Visiclear, Conmed Specimen Retrieval |
| Vertex Pharmaceuticals Incorporated | $96.00 | 2025 | |
| Olympus America INC. | $33.16 | 2021 | |
| Abbott Laboratories | $32.01 | 2019 | |
| Kci USA, INC. | $18.76 | 2023 | Prevena, V.A.C. Veraflo |
| Heron Therapeutics, INC. | $13.55 | 2021-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mastrangelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.